Robert Hureau Joins PPD
News Aug 28, 2014
Pharmaceutical Product Development, LLC (PPD) has announced the appointment of Robert Hureau as executive vice president and chief financial officer.
Hureau brings 25 years of experience and extensive financial expertise spanning the medical technology/life sciences, manufacturing and consumer sectors. Hureau begins his new role on Sept. 23 and will be based in PPD’s headquarters in Wilmington.
“Bob is an accomplished chief financial officer who will uphold PPD’s long-standing reputation as a company committed to integrity, financial discipline and sustainable growth,” said David Simmons, PPD’s chairman and chief executive officer. “We are confident Bob’s experience, strong business mind and financial acumen will complement and aid PPD's focus on delivering value for our biopharmaceutical clients.”
Hureau joined PPD from Centaur Guernsey L.P. Inc., a leading global medical technology company focused on transformational healing solutions, where he served as executive vice president and CFO.
Previously, he held a series of senior leadership positions of increasing responsibility, including senior vice president and CFO at Sensata Technologies N.V., a supplier of sensing, electrical protection, control and power management solutions, and vice president of finance with The Jean Coutu Group (PJC) U.S.A., Inc., chain of retail pharmacies.
In addition, Hureau’s experience includes financial leadership responsibilities with Ocean Spray Cranberries, Inc., and other companies in the consumer sector. Hureau is a certified public accountant and began his career at Coopers & Lybrand.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE